HIGH CORRELATION BETWEEN CLINICAL RESPONSES TO 1ST LINE AML PATIENTS TREATED WITH CYTARABINE AND IDARUBICIN AND THEIR PHARMACOLOGICAL PROFILES IN PATIENT SAMPLES MEASURED BY EXVITECH

Pau Montesinos Fernández[15],Joaquín Martínez López[17],David Martínez[15],Josefina Serrano[25],Pascual Fernández Abellán[6],Raimundo García Boyero[7],Gabriela Rodríguez[8],Pilar Herrera Puente[3],Mª Belen Vidriales[5],Mº Angeles Fernández[28],Jose Antonio Pérez Simón[26],Esperanza Lavilla Rubira[10],Santiago Jiménez Bravo de Laguna[20],Ataulfo Gonzalez Fernández[18],Carmen Burgaleta Alonso de Ozalla[2],Mar Tormo Diaz[4],Adriana Simiele[12],Susana Vives Polo[16],Guiomar Bautista Carrascosa[23],Arancha Alonso Alonso[24],Concepción Bethancourt Mateos[13],Juan Antonio López[1],Begoña Navas Elorza[11],Juan Miguel Bergua Burgués[14],Mercedes Colorado Araujo[22],Jose Angel Hernández Rivas[9],Bernando J. González González[19],Pilar martinez-Sanchez[17],Juan Antonio Vera Goñi[27],Marta Gaspar[32],Julián Gorrochategui[32],Jose Luis Rojas[32],Pilar Hernandez[32],Alicia Robles[32],Ignacio Ortega[31],Jesús Villoria[29],Federico Moscardó[15],Jaime Pérez de Oteyza[21],Iñaki Troconiz[30],Miguel Sanz [15],Joan Ballesteros[32]

[1]Complejo Hospitalario de Jaén,[2]Hospital Universitario Príncipe de Asturias,[3]Hospital Universitario Ramon y Cajal,[4]Hospital Clínico de Valencia,[5]Hospital Clinico Universitario de Salamanca,[6]Hospital General Universitario de Alicante,[7]Hospital General Universitario de Castellón,[8]Hospital General universitario Gregorio Marañón,[9]Hospital Infanta Leonor,[10]Hospital Lucus Augusti,[11]Hospital Moncloa,[12]Hospital Povisa,[13]Hospital Regional Universitario de Málaga Carlos Haya,[14]Hospital San Pedro de Alcantara,[15]Hospital Universitari i Politècnic La Fe de Valencia,[16]Hospital Universitari Germans Trias i Pujol,[17]Hospital Universitario 12 de Octubre,[18]Hospital Universitario Clínico San Carlos,[19]Hospital Universitario de Canarias,[20]Hospital Universitario de Gran Canaria Doctor Negrín,[21]Hospital Universitario Madrid Norte Sanchinarro,[22]Hospital Universitario Marqués de Valdecilla,[23]Hospital Universitario Puerta de Hierro,[24]Hospital Universitario Quirón Madrid,[25]Hospital Universitario Reina Sofía,[26]Hospital Universitario Virgen del Rocío,[27]Hospital Universitario Virgen Macarena,[28]Hospital Xeral Cies,[29]Medicxact, Madrid,[30]Universidad de Navarra, Pamplona,[31]Universidad del País Vasco, Bilbao,[32]Vivia Biotech

ABSTRACT

Background: We have overcome the limitations of 40 years of ex vivo testing with our novel Native Environment Precision Medicine approach. The aim of this study is to determine the ability of Vivia's novel test to predict the complete remission (CR) rates after induction chemotherapy with cytarabine (Ara-C) and idarubicin (Ida) in 1st line AML.

Material and Methods: Bone marrow samples from adult patients diagnosed with de novo AML in Spanish centers from the PETHEMA group were included. Whole marrow samples maintaining their Native Environment were incubated for 48h in well plates containing Ara-C, Ida, or their combination. Pharmacological responses are calculated using pharmacodynamic population Hill-based dose-effect models and drugs surface interaction analysis. Induction response was assessed according to the Cheson criteria (2003). Overall survival analysis was followed using Kapplan-Meier chart. Patients attaining a CR/CRi were classified as responders and the remaining as resistant.

Results: **377** patient samples were used to fit the dose response (DR) curves for Ara-C alone, Ida alone, and their interaction. For clinical correlation we used **142** patients with median 56 years. The strongest clinical predictors were the Area Under the Curve (AUC) of the DR of Ara-C, and the AUC of IDA. Additional prediction capabilities were associated to the difference in cell viability before and after incubation. No significance could be found for the drugs interaction parameter. Results are summarized in figure 7 in a table illustrating the correlation between clinical outcome (columns) and the test predictions (lines). From a diagnostic criteria (columns), clinically resistant patients (1st column) are not well predicted with a Sensitivity of 50%, while clinically sensitive patients (2nd column) are very well predicted with a Specificity of 95%. From a Precision Medicine criteria (Lines), patients predicted resistant (1st line) and well predicted with 80.7% positive predictive value, similar to patients predicted sensitive (2nd line) well predicted with 81.9% Negative Predictive Value. Very significant difference (P<0.0002) was observed in the overall survival analysis between the group of patients predicted as responders from those predicted as non responders (figure 8).

METHODS

ExviTech© Platform



Figure 1

Plate setup. Eight different concentrations of each drug or drug combination is run for the used treatment protocols. The max concentration used is listed.



Whole sample vs. Isolated Leukocytes: A. Correlation pairs showing differences among EC50 values from the same samples tested either as isolated leukocytes or whole sample. Error bars show the CI's of the estimated parameter. B. Dose-response curves for IDA and Cyta for the selected samples in both conditions, showing similar results form Cytarabine but very different for Idarubicin.



Figure 2

Data Analysis: performed using the population approach using NONMEM 7.2.:

- population PD Hill-based modelling of the ex vivo response vs concentration data in monotherapy (fig.2), 95% confidence interval of estimated parameters determined by bootstrapping over 1000 simulations.
- Surface interaction modelling and simulations to estimate the interaction parameter (α) as well as the corresponding confidence interval. α parameter is a measurement of synergism (>0), additivity (0) or antagonism (<0). ***Greco et al.1995.*** Pharmacol Rev June 1995 47:331-385

RESULTS

Figure 3 **Individual Dose Response Curves**



Dose-responses from 377 patient samples to Cytarabine (A) and Idarubicin (B). The Survival Index (y-axis) ranges from 100% to 0 displaying the selective AML cell depletion. Median response shown in red. For CYT 40% patient samples have resistant cells left alive at 48 h. IDA eliminates all cells within this timeframe.

Figure 4 **Interaction index**



Distribution of the interaction index calculated for the samples in the study. The central tendency was towards an additive or weak synergistic behavior although clear synergy occurred in many cases.

Figure 5 **Pharmacological Population Parameters**

SINGLE DRUG *ex vivo* PHARMACOLOGY									
DRUG	N	Efficacy (E_{max}) % Survival		Potency (EC_{50}) µ M		IPV- E_{max} %		IPV-EC_{50} %	
		Typical	RSE (%)	Typical	RSE (%)	Typical	RSE (%)	Typical	RSE (%)
CYT	377	**8.5**	1.3	**2.87**	8.1	**645**	9.1	**161**	8.4
IDA	377	**0**	-	**0.032**	9.4	ne		**207**	8.4

Individual drug typical and relative standard error values. Inter-patient variability (IPV) expressed as CV(%); ne, not estimated

Figure 6 **Logistic additive model of *ex vivo CYT-IDA* vs Clinical Outcome**

A Empirical probability distributions of the marker in resistant vs. sensitive patients



B ROC Curve



- A generalized binary logistic additive model was used to explore nonparametric relationships between either the fitted pharmacologic parameters and processed response values and the dichotomized clinical response (resistant patient [PR or PD after induction] vs. sensitive patient [CR or CRi after induction]).
- Both linear dependence and nonlinear dependence structures were evaluated for available PD parameters (cytarabine E_0, EC_{50}, I_{max} and sigmoidicity, idarubicin E_0, EC_{50} and sigmoidicity, and the interaction parameter (α)) as well as integrated terms given by the calculation of the area under the curve (AUC) for both cytarabine and Idarubicin and the volume under the surface (VUS) from the interaction analysis from the combination.
- All linear terms were non-significant. Results using individual parameters were improved by the AUCs of the modelled effect-concentration curves of both, Idarubicin and, particularly, Cytarabine which showed good predictive properties. In a lower magnitude, VUS values also showed significant predictive ability. No significance though was observed for the interaction parameter.
- The variation of the cell viability in control wells before and after incubation provided additional predictive ability: the probability of response is higher for those patients for whom cell viability does not change or changes by a small amount (cell viability decreased by 40% or lower) during incubation.
- Using a criterion based on equalling the predictive values (PV+ and PV-) to set the cut point which defines positive and negative test results is a reasonable approach to prioritize specificity over sensitivity in an objective and reproducible fashion.

Figure 7 **Correlation results summary**

Exvivo response	Clinical outcome: RESISTANT	Clinical outcome: SENSITIVE	Positive predictive value %	Subtotal
RESISTANT	21 14.8%	5 3.5%	80.77	26 18.3%
SENSITIVE	21 14.8%	95 66.9%	Negative predictive value % 81.90	116 81.7%
	Sensitivity % 50.00	Specificity % 95.00	Prediction rate % 81.69	
Subtotal	42 29.6%	100 70.4%		N 142 100.0%

Key clinical indicators: overall prediction 81.7% & NPV 81.9%

	Estimate	Selected CI: 95% Lo	Hi
Sensitivity (Se):	50%	36%	64%
Specificity (Sp):	95%	89%	98%
Positive predictive value (PV+):	81%	63%	91%
Negative predictive value (PV−):	82%	77%	86%
Positive likelihood ratio (LR+):	10.00	4.04	24.75
Negative likelihood ratio (LR−):	0.53	0.39	0.71
Kappa:	0.51	0.35	0.67
Prevalence (res):	30%		

Figure 8 **Overall survival analysis.**



The survivor functions (Kaplan-Meier) of the overall survival (OS) of patients classified as responsive or resistant using the optimal cut point over the GAM-derived marker were clearly different. The OS was much shorter in patients classified as resistant than in patients classified as responsive.
This difference was highly significant (p=0.0002)

CONCLUSIONS

- This novel test is able to predict the clinical response to Ida+Ara-C induction with 80-81%, significantly higher than the current clinical response rate of 66.7%. The test did not properly identify 21/142 that were clinically resistant and the test predicted as sensitive. This mismatched subgroup mimics the problems from molecular markers where a resistant clone present in a minority of leukemic cells cannot be detected yet drives the patient response. However, this group mismatch does not prevent a good correlation with the test predicted outcomes.
- Good predictive capabilities were identified for dose-effect area under the curve variables.
- No statistical significance with the clinical outcome was found for the interaction index from the drugs combination analysis.
- Very significant separation was found in the overall survival analysis between the two branches of responsive and resistant cases according to the test results.

Grants supporting this work:
Programa PRIMER Castilla y Leon (04/09/AS/0028), ADE Medicina Personalizada 2007 (04/06/SA/0009),Programa Reindustrialización 2011 MITYC (REI-040000-2011-777), Programa Torres Quevedo, MICINN Programa Inncorpora, MICINN

www.viviabiotech.com

ACKNOWLEDGEMENTS

Special Thanks to the Patients and Hospitals for Providing the Samples (listed alphabetically)

- Complejo Hospitalario de Jaén, JAEN
- Complejo Hospitario Xeral Cíes de Vigo, VIGO
- Hospital Carlos Haya, MÁLAGA
- Hospital Clínico San Carlos, MADRID
- Hospital de la Santa Creu i Sant Pau, BARCELONA
- Hospital de Madrid Norte Sanchinarro, MADRID
- Hospital Doce de Octubre, MADRID
- Hospital General Universitario de Alicante, ALICANTE
- Hospital Infanta Sofía, MADRID
- Hospital Moncloa, MADRID
- Hospital Povisa, PONTEVEDRA
- Hospital Quirón, MADRID
- Hospital Ramón y Cajal, MADRID
- Hospital Universitario Central de Asturias, OVIEDO
- Hospital Universitario de Canarias, TENERIFE
- Hospital Universitario de Gran Canaria Doctor Negrín, GRAN CANARIA
- Hospital Universitario General de Castellón, CASTELLÓN
- Hospital Universitario Gregorio Marañón, MADRID
- Hospital Universitari i Politecnic La Fe, VALENCIA
- Hospital Universitario Infanta Leonor, MADRID
- Hospital Universitario Lucus Augusti, LUGO
- Hospital Universitario Príncipe de Asturias, MADRID
- Hospital Universitario Reina Sofía, CÓRDOBA
- Hospital Universitario Virgen Macarena, SEVILLA